π©Ί Asthma drug delay spikes healthcare costs
A delay in the Dupilumab medication has significantly increased the financial burden for asthma patients. This issue was highlighted by Nicola Hanania, MD, in The American Journal of Managed Care. The delay has resulted in a documented 32% rise in associated asthma treatment costs. This situation underscores the complex economic challenges within chronic disease management. Further analysis is needed to mitigate these rising healthcare expenditures moving forward. π©Ί